High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy.
about
Low level myocardial parvovirus B19 persistence is a frequent finding in patients with heart disease but unrelated to ongoing myocardial injury.Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure.Human parvovirus B19: a mechanistic overview of infection and DNA replication.Differences in virus prevalence and load in the hearts of patients with idiopathic dilated cardiomyopathy with and without immune-mediated inflammatory diseasesBones hold the key to DNA virus history and epidemiology.Chronic Lyme Disease and Co-infections: Differential DiagnosisThe effects of co-infection with human parvovirus B19 and Plasmodium falciparum on type and degree of anaemia in Ghanaian childrenMolecular phenotypes of human parvovirus B19 in patients with myocarditis.Viral myocarditis: potential defense mechanisms within the cardiomyocyte against virus infection.Viral myocarditis: from experimental models to molecular diagnosis in patients.Classification and histological, immunohistochemical, and molecular diagnosis of inflammatory myocardial disease.Endomyocardial biopsy safety and clinical yield in pediatric myocarditis: An Italian perspective.Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature.Human Parvoviruses.A distinct subgroup of cardiomyopathy patients characterized by transcriptionally active cardiotropic erythrovirus and altered cardiac gene expression.Genotype-specific effects on left ventricular function in parvovirus B19-positive patients with dilated cardiomyopathy.Outcome predictors in dilated cardiomyopathy or myocarditis.Predictors of outcome in patients with parvovirus B19 positive endomyocardial biopsy.Evaluation of the diagnostic work-up in children with myocarditis and idiopathic dilated cardiomyopathy.The presence of enterovirus, adenovirus, and parvovirus B19 in myocardial tissue samples from autopsies: an evaluation of their frequencies in deceased individuals with myocarditis and in non-inflamed control hearts.Persistence of human parvovirus B19 in tissues from adult individuals: a comparison with serostatus and its clinical utility.Pathophysiological mechanisms of parvovirus B19 infectionFatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab.Viral myocarditis: a prime example for endomyocardial biopsy-guided diagnosis and therapy.miRNA as activity markers in Parvo B19 associated heart disease.Therapeutic implications of a combined diagnostic workup including endomyocardial biopsy in an all-comer population of patients with heart failure: a retrospective analysis.Sudden cardiac death, borderline myocarditis and molecular diagnosis: evidence or assumption?Genotypes of erythrovirus B19, their geographical distribution & circulation in cases with various clinical manifestations.Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activityAncient human parvovirus B19 in Eurasia reveals its long-term association with humansParvovirus B19 Achievements and Challenges
P2860
Q30318661-CE5D0C5B-EFB3-42F3-BA4E-24973C82F16DQ34618009-9AEDDCE0-C2BA-46E3-8E57-0C87A8995F69Q35751511-BEC5AB9A-AFDB-4A2D-930C-5AE7B78FFAD5Q36154780-AFB4E9ED-71BC-4081-B581-9AEB7D72C035Q36324310-65D4559D-6104-43EA-BD34-33A395B3C9BEQ36589833-DE61741B-3C1B-453E-B115-54136CFCE57EQ36768164-E711BF39-011C-4EDC-8219-778DBF2F44F7Q37722777-672C3958-3C28-416D-A442-CB4FC1D41934Q37876416-2568ECD3-F831-4990-9D66-49EAA07D7DCBQ38052447-0F7C9DD3-BE52-4CCA-BBBE-71878CCD7B59Q38055369-2C188FAA-B616-4058-BCF7-CC5B51F916E1Q38618528-38C53F78-4472-4831-8409-BF0981947FCDQ38810914-03BC6017-5EF8-47D0-8602-3CAF48512A42Q38996997-CD66BF47-C8F7-4C23-868E-EC13D13F03ADQ39369050-5B85355C-6719-44FC-AEB5-AD369D05F993Q39718255-EE95319F-85BB-4B75-97E9-92BDF7B14BE7Q40181302-A3602459-B256-42B5-A53C-C266FE28BFF0Q40777639-2156BFE8-89DA-4C53-925D-D964362C10EBQ42192353-B2386B4A-DDE3-4083-A3C3-D4CFC1FBAF66Q42221396-275946CD-B0D6-46BA-9617-785CAE2713B0Q42221705-B8FB5682-6795-4D15-A4D2-B64692F491FEQ42789700-F5CB5E83-9D63-4226-902F-2DEC178CFC36Q47916862-36A06C90-CB8A-49FE-AB36-E28DA1BFE9F7Q52660853-A79C2A0F-7E41-499C-9060-E41B3C81502CQ52887298-067CFE5A-CD62-4C9D-BC2F-D8FD5F3D5E3BQ53848811-11302A28-B001-49B5-87DA-F358B42ABD2BQ54335341-4EB59F55-E972-473C-A2FD-0C00AACA84D2Q55686767-F1F9E9DE-49D3-4353-BA00-8272294D8A80Q56964618-A4EDAFD6-4C30-4D28-B96B-3DC0C4BD4591Q56965812-26875719-9772-4EBD-AC66-D90F0A25E3F2Q58666387-1727BF8C-B4C4-463C-857B-CCCEFCB4C891
P2860
High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
High prevalence of human parvo ...... is or dilative cardiomyopathy.
@en
High prevalence of human parvo ...... is or dilative cardiomyopathy.
@nl
type
label
High prevalence of human parvo ...... is or dilative cardiomyopathy.
@en
High prevalence of human parvo ...... is or dilative cardiomyopathy.
@nl
prefLabel
High prevalence of human parvo ...... is or dilative cardiomyopathy.
@en
High prevalence of human parvo ...... is or dilative cardiomyopathy.
@nl
P2093
P2860
P356
P1476
High prevalence of human parvo ...... is or dilative cardiomyopathy.
@en
P2093
Daniela Huzly
Martin Enders
Ralph Hahn
Stefan Pollak
Thomas Schenk
P2860
P304
P356
10.1128/JCM.01672-08
P407
P577
2008-11-12T00:00:00Z